[{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Cologne University Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"DZIF-10c","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Boehringer Ingelheim GmbH \/ Cologne University Hospital","highestDevelopmentStatusID":"7","companyTruncated":"Boehringer Ingelheim GmbH \/ Cologne University Hospital"},{"orgOrder":0,"company":"Corat Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"COR-101","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Corat Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Corat Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Corat Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"CureVac","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"H5N1","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"CureVac","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"CureVac \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"CureVac \/ Inapplicable"},{"orgOrder":0,"company":"BioNTech","sponsor":"CEPI","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Vaccine","year":"2024","type":"Partnership","leadProduct":"BNT165e","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"BioNTech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BioNTech \/ CEPI","highestDevelopmentStatusID":"7","companyTruncated":"BioNTech \/ CEPI"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          EPS
                          Not Confirmed
                          EPS
                          Not Confirmed

                          Details : BioNTech and CEPI aim to enhance local R&D, clinical and commercial-scale manufacturing capacities to develop potential mRNA vaccines like BNT165 against malaria, mpox and tuberculosis in Africa.

                          Product Name : BNT165e

                          Product Type : Vaccine

                          Upfront Cash : Undisclosed

                          May 29, 2024

                          Lead Product(s) : BNT165e

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : CEPI

                          Deal Size : $145.0 million

                          Deal Type : Partnership

                          blank

                          02

                          EPS
                          Not Confirmed
                          EPS
                          Not Confirmed

                          Details : H5N1 is a pre-pandemic vaccine candidate currently undergoing evaluation in early-stage clinical trials with patients for treating the H5N1 subtype of influenza A virus.

                          Product Name : H5N1

                          Product Type : Vaccine

                          Upfront Cash : Inapplicable

                          April 24, 2024

                          Lead Product(s) : H5N1

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          EPS
                          Not Confirmed
                          EPS
                          Not Confirmed

                          Details : COR-101 is a fully human IgG monoclonal antibody isolated from recovered COVID-19 patients. COR-101 prevents SARS-CoV-2 from infecting new cells by binding the surface of the virus thereby preventing that the virus attaches to human cells.

                          Product Name : COR-101

                          Product Type : Antibody

                          Upfront Cash : Inapplicable

                          April 23, 2021

                          Lead Product(s) : COR-101

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          EPS
                          Not Confirmed
                          EPS
                          Not Confirmed

                          Details : Phase 1/2a clinical trials will evaluate the safety, pharmacokinetics, and antiviral activity of BI 767551 administered by intravenous infusion and by inhalation. The first patients have already been enrolled.

                          Product Name : BI 767551

                          Product Type : Antibody

                          Upfront Cash : Inapplicable

                          December 18, 2020

                          Lead Product(s) : DZIF-10c

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Cologne University Hospital

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          EPS
                          Not Confirmed
                          EPS
                          Not Confirmed

                          Details : EIB debt instrument will support BioNTech’s global development of BNT162 for prevention of COVID-19 infection as well as scale-up of manufacturing capacity in Europe as part of the company’s global development and supply strategy.

                          Product Name : BNT162

                          Product Type : Vaccine

                          Upfront Cash : Undisclosed

                          November 06, 2020

                          Lead Product(s) : BNT162

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : European Investment Bank

                          Deal Size : $112.3 million

                          Deal Type : Financing

                          blank

                          06

                          EPS
                          Not Confirmed
                          EPS
                          Not Confirmed

                          Details : The potential vaccine is one of the two most advanced candidates that BioNTech is working on with its partner Pfizer Inc and they received “fast track” status this week from the U.S. Food and Drug Administration which is designed to speed up the regu...

                          Product Name : BNT162

                          Product Type : Vaccine

                          Upfront Cash : Inapplicable

                          July 16, 2020

                          Lead Product(s) : BNT162

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Fosun Pharmaceutical

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          07

                          EPS
                          Not Confirmed
                          EPS
                          Not Confirmed

                          Details : First clinical trial of a COVID-19 vaccine candidate in Germany. Pfizer and BioNTech plan to initiate trials for BNT162 in the United States upon regulatory approval, which is expected shortly.

                          Product Name : BNT162

                          Product Type : Vaccine

                          Upfront Cash : Inapplicable

                          April 29, 2020

                          Lead Product(s) : BNT162

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          08

                          EPS
                          Not Confirmed
                          EPS
                          Not Confirmed

                          Details : BioNTech and Pfizer are jointly developing BNT162. The trial is the first clinical trial of a COVID-19 vaccine candidate to start in Germany, and is part of a global development program.

                          Product Name : BNT162

                          Product Type : Vaccine

                          Upfront Cash : Inapplicable

                          April 22, 2020

                          Lead Product(s) : BNT162

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank